The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.
The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.
The findings give hope for a vaccine for sarcoma, called CMB305, an immunotherapy strategy that involves using an engineered virus to teach patients’ immune systems to recognize and kill tumor cells.
The findings will be presented by Dr. Seth Pollack, a physician-scientist at Fred Hutchinson Cancer Research Center, June 5 in a poster at the American Society of Clinical Oncology annual meeting in Chicago.
The poster presentation reinforces the results of an early-stage clinical trial led by Dr. Neeta Somaiah of MD Anderson Cancer Center and to be presented June 2 at the ASCO meeting. Pollack is a senior investigator on the trial.
Read more at Fred Hutchinson Cancer Research Center
Image: Dr. Seth Pollack, a physician-scientist at Fred Hutch who specializes in sarcoma (Credit: Bo Jungmayer / Fred Hutch News Service)
